The Effects of Haedoksamul-tang on Oxidative Stress and Hyperlipidemia in LPS-induced ICR Mouse

Gyu-ho Choi; Yu-sun Jung; Hyeon-cheol Shin; Choi, Gyu-ho; Jung, Yu-sun; Shin, Hyeon-cheol

doi:10.13048/jkm.16008

JKM > Volume 37(1); 2016 > Article

Choi, Jung, and Shin: The Effects of Haedoksamul-tang on Oxidative Stress and Hyperlipidemia in LPS-induced ICR Mouse

Original Article

The Journal of Korean Oriental Medicine 2016; 37(1): 77-89.

Published online: March 31, 2016

DOI: https://doi.org/10.13048/jkm.16008

The Effects of Haedoksamul-tang on Oxidative Stress and Hyperlipidemia in LPS-induced ICR Mouse

Gyu-ho Choi, Yu-sun Jung, Hyeon-cheol Shin

Department of Internal Medicine of Korean Medicine, College of Korean Medicine, Dae-gu Haany University

Correspondence to: 신현철, 대구한의대학교 한의과대학 내과학교실, Tel: +82-54-281-0055, Fax: +82-54-281-7464, E-mail: ungaeshin@naver.com

Received February 15, 2016 Revised March 21, 2016 Accepted March 28, 2016

Abstract

Objectives:

The present study was conducted to examine whether Haedoksamul-tang (HS), a traditional oriental herbal medicine, have beneficail effects on anti-inflammation and dyslipidemia in lipopolysaccharide (LPS)-induced ICR mouse.

Methods:

Twenty four 8-week old male ICR mouse were divided into four groups: normal untreated; LPS treatment only; HS 10 mg/kg plus LPS treatment; and HS 30 mg/kg plus LPS treatment. HS was orally administered per day for 2days. Twenty-four hours after LPS injection (10 mg/kg/day, i.p.), all the mice were sacrificed, and serological changes were evaluated. The levels of nuclear factor-κB (NF-κB), sterol regulatory element-binding transcription protein 1 (SREBP-1) activity and cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), tumor necrosis factor a (TNF-a), monocyte chemotactic protein 1 (MCP-1), acetyl-CoA carboxylase a (ACCa) expression were analyzed in Western blot analysis.

Results:

HS inhibited oxidative stress in the liver of LPS-induced ICR mice. The LPS-induced ICR mice exhibited the increase of NF-κB activity and COX-2, iNOS, TNF-a, MCP-1 expressions in the liver, while HS treatment significantly inhibited them. Moreover, The administration of HS significantly decreased the elevated serum triglyceride and down-regulated the levels of SREBP-1, ACCa in the liver of LPS-induced ICR mice.

Conclusions:

In conclusion, HS could have hepato-protective effects against the oxidative stress-related inflammation and abnormal lipid metabolism.

Keywords: Haedoksamul-tang, inflammation, dyslipidemia, NF-κB, SREBP-1

Fig. 1.

Inhibition effects of HS on serum and hepatic oxidative stress in LPS-induced ICR mice. Serum ROS (A), hepatic ROS (B), hepatic TBARS (C) levels. N: normal group, Veh: vehicle-treated mice, HS10: HS 10 mg/kg treated mice, HS30: HS 30 mg/kg treated mice. Bars represent means ± SD. ^** P < 0.01 versus vehicle-treated mice values.

Fig. 2.

Effects of HS on NF-κBp65 activity in LPS-induced ICR mice liver. N: normal group, Veh: vehicle-treated mice, HS10: HS 10 mg/kg treated mice, HS30: HS 30 mg/kg treated mice. Histone was used for loading control. Bars represent means ± SD. ^* P < 0.05, ^*** P < 0.001 versus vehicle-treated mice values.

Fig. 3.

Effects of HS on COX-2 and iNOS expressions in LPS-induced ICR mice liver. COX-2 (A) and iNOS (B) protein expressions in liver. N: normal group, Veh: vehicle -treated mice, HS10: HS 10 mg/kg treated mice, HS30: HS 30 mg/kg treated mice. ß-actin was used for loading control. Bars represent means ± SD. ^* P < 0.05, ^** P < 0.01, ^*** P < 0.001 versus vehicle-treated mice values.

Fig. 4.

Effects of HS on TNF-a and MCP-1 expressions in LPS-induced ICR mice liver. TNF-a (A) and MCP-1 (B) protein expressions in liver. N: normal group, Veh: vehicle-treated mice, HS10: HS 10 mg/kg treated mice, HS30: HS 30 mg/kg treated mice. ß-actin was used for loading control. Bars represent means ± SD. ^* P < 0.05, ^** P < 0.01, ^*** P < 0.001 versus vehicle-treated mice values.

Fig. 5.

Effects of HS on serum and hepatic triglyceride levels in LPS-induced ICR mice. Serum triglyceride (A), hepatic triglyceride (B) levels. N: normal group, Veh: vehicle-treated mice, HS10: HS 10 mg/kg treated mice, HS30: HS 30 mg/kg treated mice. Bars represent means ± SD. ^* P < 0.05, ^** P < 0.01, ^*** P < 0.001 versus vehicle-treated mice values.

Fig. 6.

Effects of HS on SREBP-1 activity and ACCa expression in LPS-induced ICR mice liver. SREBP-1 (A) activity and ACCa (B) protein expression in liver. N: normal group, Veh: vehicle-treated mice, HS10: HS 10 mg/kg treated mice, HS30: HS 30 mg/kg treated mice. Histone or ß-actin was used for loading control. Bars represent means ± SD. ^* P < 0.05, ^** P < 0.01, ^*** P < 0.001 versus vehicle-treated mice values.

Table 1.

Composition of Haedoksamul-tang

Herb name	Scientific name	Amounts (g)
黃芩	Scutellaria baicalensis George	4
黃連	Coptis chinensis Franch.	4
黃柏	Phellodendron amurense Ruprecht	4
梔子	Gardenia jasminoides Ellis	4
當歸	Angelica acutiloba (S. et Z.) Kitagawa	4
川芎	Cnidium officinale Makino	4
白芍藥	Paeonia latiflora Pall.	4
生乾地黃	Rehmannia glutinosa (Gaetner) Libosch.	4

	Total	32

참고문헌

1.. Johan F. Immunity, atherosclerosis and cardiovascular disease. BMC med. 2013; 11:117–29.

2.. Feng X, Zhang Y, Xu R, Xie X, Tao L, Gao H, et al. Lipopolysaccharide up-regulates the expression of Fcalpha/mu receptor and promotes the binding of oxidized low-density lipoprotein and its IgM antibody comples to activated human macrophages. Atherosclerosis. 2010; 208:396–405.

3.. Wiesner P, Choi SH, Almazan F, Benner C, Huang W, Diehl CJ, et al. Low doses of lipopolysaccharide and minimally oxidized low-density lipoprotein cooperatively activate macrophages via nuclear factor kappa B and activator protein-1: possible mechanism for acceleration of atherosclerosis by subclinical endotoxemia. Circ Res. 2010; 107:56–65.

4.. Maitra U, Li L. Molecular mechanisms responsible for the ruduced expression of cholesterol transporters from macrophages by low-dose endotoxin. Arterioscler Thromb Vasc Biol. 2013; 33:24–33.

5.. Vikatmaa P, Lajunen T, Ikonen TS, Pussinen PJ, Leinonen M, Saikku P, et al. Chlamydial lipopolysaccharide (cLPS) is present in atherosclerotic and aneurysmal arterial wall--cLPS levels depend on disease manifestation. Cardiovasc Pathol. 2010; 19:1. 48–54.

6.. Jean L, Bret D, Chistophe C. Systemic capsaicin pretreatment fails to bolck the decrease in food-motivated behavior induced by lipopolysaccharide and interleukin-1ß. Brain Research Bul. 1997; 42:443–9.

7.. Sharifov OF, Nawar G, Ternovov W, Mishra VK, Litovsky SH, Palqunachare MN, et al. Cationic peptide mR18L with lipid lowering properties inhibits LPS-induced systemic and liver inflammation in rats. Biochem Biophys Res Commun. 2013; 436:4. 705–10.

8.. Kim ID, Kang KS, Kwon RH, Yang JO, Lee JS, Ha BJ. The effect of Rubus coreanum Miquel against lipopolysaccharide-induced oxidative stress and lipid metaobolism. J. Fd Hyg. Safety. 2007; 22:3. 213–7.

9.. Ju JH. Dan-gye-sim-beop-bu-yeo. Seoul: Daesung Publishing Co. Ltd;1982. p. 714

10.. Lee SI. Cheon-jin-cheo-bang-hea-sheol. Seoul: Sheong-bo-sa;1995. p. 289–91.

11.. Kim ES. A experimental study of Hwangryeonheadock-Tang and Onchung-Eum on hyperlipidemia & hypertension. J. of Korean Medicine. 1999; 20:1. 185–96.

12.. Kim YH, Jo HB. Anti-inflammatory effects of Haedoksamul-tang in RAW 264.7 cells. J. of Oriental Obstetrics & Gynecology. 2008; 21:2. 166–83.

13.. Beom HB. Effects of Onchungeum and Gamionchungeum on the antiallergic response and blood coagulation. J. of Kyung Hee University. 1990; 6:4. 490–9.

14.. Jeon YG. Effects of Haedoksamul-tang on Trimelliticanhydride-induced contact hypersensitivity in a mouse model. 2010; 1–41.

15.. Seo M, Jeon BH, Woo WH, Jeong WY. Effect of Onchengyeum on the damaged liver cell by carbon tetrachloride in rats. Korean J. Oriental Physiology & Pathology. 1989; 11:2. 27–36.

16.. Im HJ, Hwang CY, Gang HC, Kim NG, Gwon IH. Inhibitory effects of Onchumgeum on cytokine production from phytohaemagglutin-stimulated peripheral blood mononuclear cells of behcets patients. Korean J. Oriental Physiology & Pathology. 2002; 16:4. 768–73.

17.. Zhu GF, Guo HJ, Huang Y, Wu CT, Zhang XF. Eriodictyol, a plant flavonoid, attenuates LPS-induced acute lung injury through its antioxidative and anti-inflammatory activity. Exp Ther Med. 2015; 10:6. 2259–66.

18.. Heo J. Dong-ui-bo-gam. Seoul: Bubin Publishing Co. Ltd;2007. 416:p. 455

19.. Rush GF, Gorski JR, Ripple MG, Sowinski J, Bugelski P. Organic hydroperoxide -induced lipid peroxidation and cell death in isolated hepatocytes. Toxicol Appl Pharmacol. 1985; 78:473–83.

20.. Izeboud CA, Hoebe KH, Grootendorst AF, Nijmeijer SM, van Miert AS, Witkamp RF, et al. Endotoxin-induced liver damage in rats is minimized by beta 2-adrenoceptor stimulation. Inflamm Res. 2004; 53:93–9.

21.. Munford RS. Severe sepsis and septic sock: the role of gram-negative bacteremia. Annu Rev Pathol. 2006; 1:467–96.

22.. Kleemann R, Verschuren L, van Erk M, Nikolsky Y, Verheij ER, Smilde AK, et al. Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. Genome Biol. 2007; 8:R200

23.. Xu X, Hu J, McGrath BC, Cavener DR. GCN2 in the brain programs PPARγ2 and triglyceride storage in the liver during perinatal development in response to maternal dietary fat. PLos One. 2013; 8:10. e75917

24.. Liu RH, Hotchkiss JH. Potential genotoxicity of chronically elevated nitirc oxide: a review. Mutat. Res. 1996; 339:73–89.

25.. Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis. J Clin Invest. 2001; 107:255–64.

26.. Thuberg BL, Collins T. The nuclear factor-B/inhibitor of B autoregulatory system and atherosclerosis. Curr Opin Lipidol. 1998; 9:387–96.

27.. Wang QS, Xiang Y, Cui YL, Lin KM, Zhang XF. Dietary blue pigments derived from Genipin, attenuate inflammation by inhibiting LPS-Induced iNOS and COX-2 expression via the NF-κB inactivation. PLos One. 2012; 7:3. 1–11.

28.. Kwon HJ, Sung BK, Kim JW, Lee JH, Kim ND, Yoo MA, et al. The effect of lipopolysaccharide on enhanced inflammatory process with age: modulation of NF-κB. J. Amer. Aging Assoc. 2001; 24:163–72.

29.. Napoli C, de Nigris F, Williams-Ignarro S, Pignalosa O, Sica V, Ignarro LJ. Nitric oxide and atherosclerosis: an update. Nitric Oxide. 2006; 15:265–79.

30.. Baldwin AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1996; 14:649–83.

31.. DeGraba TJ. Expression of inflammatory mediators and adhesion molecules in human atherosclerotic plaque. Neurology. 1997; 49:Supple 4. S15–9.

32.. Fassbender K, Rossol S, Kammer T, Daffertshofer M, Wirth S, Dollman M, et al. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci. 1994; 122:2. 135–9.

33.. Adams DH, Lioyd AF. Chemokines: leukocyte recruitment and activation cytokines. Lancet. 1997; 349:490–5.

34.. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997; 89:331–40.

35.. Weber LW, Boll M, Stampfl A. Maintaining cholesterol homeostasis: sterol regulatory element-binding proteins. World J Gastroenterol. 2004; 10:21. 3081–7.

36.. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002; 109:1125–31.

37.. Foufelle F, Ferre P. New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem J. 2002; 366:377–91.

38.. Ferre P, Foretz M, Azzout-Marniche D, Becard D, Foufelle F. Sterol-regulatory-element-binding protein 1c mediates insulin action on hepatic gene expression. Biochemical Society Transactions. 2001; 29:4. 547–52.

39.. Horton JD. Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis. Biochemical Society Transactions. 2001; 30:6. 1091–5.

40.. Tong L. Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and attractive target for drug discovery. Cell Mol Life Sci. 2005; 62:16. 1784–803.

41.. Munday MR. Regulation of mammalian acetyl-CoA carboxylase. Biochem Soc Trans. 2002; 30:6. 1059–64.